021-51111890
购物车（）
sales@molnova.cn
Nintedanib esylate
CAS No. 656247-18-6
Nintedanib esylate ( BIBF1120 esylate;BIBF-1120 esylate )
产品货号. M15495 CAS No. 656247-18-6
Nintedanib esylate (BIBF1120 esylate) is a potent triple angiokinase (VEGFR/PDGFR/FGFR) inhibitor.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥292 | 有现货 |
|
| 10MG | ￥421 | 有现货 |
|
| 25MG | ￥527 | 有现货 |
|
| 50MG | ￥624 | 有现货 |
|
| 100MG | ￥867 | 有现货 |
|
| 200MG | ￥1353 | 有现货 |
|
| 500MG | ￥2697 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Nintedanib esylate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Nintedanib esylate (BIBF1120 esylate) is a potent triple angiokinase (VEGFR/PDGFR/FGFR) inhibitor.
-
产品描述Nintedanib esylate (BIBF1120 esylate) is a potent triple angiokinase (VEGFR/PDGFR/FGFR) inhibitor with IC50 of 5/38/18/104/5 nM for VEGFR-2/FGFR-1/PDGFRα/VEGFR-1/VEGFR-3, respectively; inhibits MAPK and Akt signaling pathways, show inhibition of cell proliferation (EC50=10-80 nM); is fully efficacious in xenograft models and orally active.Lung Cancer Approved
-
同义词BIBF1120 esylate;BIBF-1120 esylate
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR1;VEGFR2;VEGFR3;FGFR1;FGFR2;FGFR3;PDGFRα;PDGFRβ
-
研究领域Cancer
-
适应症Lung Cancer
化学信息
-
CAS Number656247-18-6
-
分子量649.76
-
分子式C33H39N5O7S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
-
化学全称1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, ethanesulfonate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Roth GJ, et al. J Med Chem. 2009 Jul 23;52(14):4466-80.
2. Hilberg F, et al. Cancer Res. 2008 Jun 15;68(12):4774-82.
3. Kudo K, et al. Clin Cancer Res. 2011 Mar 15;17(6):1373-81.
2. Hilberg F, et al. Cancer Res. 2008 Jun 15;68(12):4774-82.
3. Kudo K, et al. Clin Cancer Res. 2011 Mar 15;17(6):1373-81.
产品手册
关联产品
-
AG-13958
AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor ?for the treatment of age-related macular degeneration.
-
AKB-6899
AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages.
-
TAK-593
TAK-593 is an effective VEGFR and PDGFR family inhibitor.
